1 y for slow responders or those with residual mediastinal disease.

2 ratification of early-stage HL patients with mediastinal disease and thus contribute to risk-adapted,

3 Patients with favorable stage I/II (nonbulky mediastinal disease) and those with bulky mediastinal di

4                      LDH level at diagnosis, mediastinal disease, and combined BM-positive/CNS-positi

5 radiation therapy was given to patients with mediastinal disease at presentation.

6 allium (90% +/- 5) scintigraphic findings of mediastinal disease did not differ significantly (P = .4

7 28%) patients with no pathologically evident mediastinal disease expressed telomerase in at least one

8                                        Bulky mediastinal disease greater than one third transthoracic

9 ky mediastinal disease) and those with bulky mediastinal disease or stage III/IV were scanned after 8

10 thermore, among the patients with refractory mediastinal disease, our model distinguished those who w

11  male sex, low initial hemoglobin, and bulky mediastinal disease predicting for LF.

12 ies, such as pulmonary fibrosis, pleural and mediastinal disease, solid lesions, bronchial disease, a

13 e sex; stage IIB, IIIB, or IV disease; bulky mediastinal disease; WBC more than 13.5 x 10(3)/mm3; and

14  Male sex, low initial hemoglobin, and bulky mediastinal disease were prognostic indicators of LF.

15 All study patients were judged to be free of mediastinal disease with CT and the clinical criteria.